Gilead and Arcus Present P-II Study (ARC-7) Results of Domvanalimab as 1L Treatment of Non-Small Cell Lung Cancer at ASCO 2023
Shots:
- The interim analysis from the P-II study evaluating domvanalimab + zimberelimab (doublet) & domvanalimab + zimberelimab and etrumadenant (triplet) vs zimberelimab monotx. in a ratio (1:1:1) in 150 patients with PD-L1 TPS ≥50% and no EGFR or ALK mutations
- As the time of data cutoff of Feb 2023, improvement in PFS vs zimberelimab monotx. with a median follow-up time of ~18mos., 33% reduction in risk of disease progression or death for doublet & 28% for triplet
- Zimberelimab monotx./domvanalimab-doublet/triplet arms, m-PFS (5.4/9.3/9.9mos.; 6 & 12mos. PFS rate (45% & 25%/58% & 41%/62% & 44%); ORR (30%/40%/44%); CR (2%/2%/0%); confirmed & pending PR (28% & 0%/36% & 2%/44% & 0%); SD (32%/36%/32%); PD (24%/8%/14%); NE (14%/16%/10%); incidence of infusion-related reactions was low (4%/4%/12%) & improved efficacy across multiple measures with no unexpected safety signals
Ref: Gilead | Image: Gilead
Related News:- Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
